NAMS
Wall Street’s vibe check: still pretty optimistic
NewAmsterdam Pharma just got the analyst treatment, and the takeaway is basically: Wall Street isn’t rushing for the exits. Twelve analysts now rate the stock a "Moderate Buy," with a mix of 1 sell, 1 hold, 9 buys, and 1 strong buy. The average 12-month price target sits at $48.
Why you should care
For investors, analyst consensus can act like a weather forecast. It doesn’t guarantee sunshine, but it can shape expectations — especially for a biotech name where sentiment can swing faster than a group chat after bad news.
The fine print is doing a little backflipping
This isn’t a pure victory lap, though. The same article flags hefty insider selling over the last quarter, including CEO Michael H. Davidson unloading 443,707 shares worth about $14.75 million. A director also sold 44,619 shares, and insiders together disposed of 1,313,286 shares worth roughly $42.96 million.
That doesn’t automatically mean trouble — insiders sell for all sorts of reasons — but when the people closest to the company are trimming while analysts stay upbeat, you may want to pay attention to whether the market is getting ahead of the story.
Big picture
The analyst note is supportive, but the insider selling adds a little side-eye energy. If you own NAMS, this is one of those moments where you get the classic market combo platter: optimism on the sell-side, caution from the people inside the building.